0000000000933253

AUTHOR

Irene Modesto

showing 23 related works from this author

Meta-analysis of the placebo rates of clinical relapse and severe endoscopic recurrence in post-operative Crohn's disease

2008

Meta-analysis of the placebo rates of clinical relapse and severe endoscopic recurrence in postoperative Crohn's disease. Renna S, Cammà C, Modesto I, Cabibbo G, Scimeca D, Civitavecchia G, Mocciaro F, Orlando A, Enea M, Cottone M. Dipartimento di Medicina, Pneumologia e Fisiologia della Nutrizione Umana, Università di Palermo, Palermo, Italy. BACKGROUNDS & AIMS: The benefit of therapy for prevention of postoperative recurrence of Crohn's disease (CD) is limited. Clinical relapse and severe endoscopic recurrence are the main outcomes in the evaluation of trials on prevention of recurrence. The aim of this meta-analysis was to focus on knowledge of the placebo rates of relapse and recurr…

medicine.medical_specialtyMEDLINEDiseasePlaceboEndoscopy Gastrointestinallaw.inventionCrohn DiseaseRandomized controlled triallawInternal medicineSecondary PreventionmedicineHumansPostoperative PeriodDigestive System Surgical ProceduresRandomized Controlled Trials as TopicCrohn's diseaseHepatologybusiness.industryGastroenterologyOdds ratioPrognosismedicine.diseaseConfidence intervalSurgeryMeta-analysisMeta-analysis placebo relapse severe endoscopic recurrencebusiness
researchProduct

Leukocytapheresis in patients with moderate-severe steroid-dependant ulcerative colitis: Clinical Response without Endoscopic Response

2006

medicine.medical_specialtybusiness.industrymedicine.medical_treatmentGastroenterology.medicine.diseaseGastroenterologyUlcerative colitisSteroidInternal medicinemedicineImmunology and AllergyIn patientDependantbusinessInflammatory Bowel Diseases
researchProduct

Is 5-ASA Still the Treatment of Choice for Ulcerative Colitis?

2010

5-Amino-salacylic acid (5-ASA) is up to now the treatment of choice in the induction and maintenance of remission of mild-to-moderate ulcerative colitis (UC). Sulfasalazine, despite similar efficacy, is hampered by more side effects, but in presence of peripheral arthopaties it remains the treatment of choice. The new delayed release MMX formulation seems to be promising in reducing compliance problems, but further studies are warranted to show the superiority of new MMX formulation compared with the older formulations of 5-ASA. Some trials evaluated also the efficacy and safety of once-daily dosing of older 5-ASA formulations in maintenance of remission, finding a greater adherence to ther…

medicine.medical_specialtySettore MED/09 - Medicina InternaClinical BiochemistryPharmacologyPlaceboSulfasalazineInternal medicineDrug DiscoverymedicineHumansDosingColitisMesalamine5-ASA Treatment Choice Ulcerative ColitisPharmacologyClinical Trials as Topicbusiness.industryAnti-Inflammatory Agents Non-Steroidalmedicine.diseaseUlcerative colitisTacrolimusRegimenMolecular MedicineColitis UlcerativeRosiglitazonebusinessmedicine.drugCurrent Drug Targets
researchProduct

The role of CARD15 mutations and smoking in the course of Crohn's disease in a Mediterranean area.

2008

To evaluate the role of CARD15 mutations and smoking in the main events of Crohn's disease (CD).A total of 182 patients with CD were included in a prospective study in order to evaluate the role of CARD15 mutations and smoking in the main outcomes of disease course: first operation and surgical recurrence. The following variables were evaluated in a univariable and multivariable analysis: age, sex, site of disease, pattern, smoking habit, extraintestinal manifestations, duration of disease, and CARD15 mutation. The Kaplan-Meier method for survival curves and Cox model for multivariable analysis were, respectively, used.A total of 110 patients were operated on and 32 were reoperated on. The …

AdultMaleReoperationmedicine.medical_specialtyPathologyGenotypeNod2 Signaling Adaptor ProteinDiseaseCrohn DiseaseRecurrenceInternal medicineMedicineHumansCrohn's diseaseHepatologybusiness.industryCrohn diseaseSmokingGastroenterologymedicine.diseasePrognosisdigestive system diseasesMutation (genetic algorithm)MutationMediterranean areaFemalebusinessThe American journal of gastroenterology
researchProduct

Methodological Problems in RCTs on IBD

2012

Abstract: Randomized controlled trials (RCTs) are the gold standard method for developing evidence-based medicine in inflammatory bowel disease (IBD). Methodological problems in RCTs in IBD concern different aspects such as the definition of the study population due to the extreme variability of patients with IBD, the indices of disease activity, a clearly defined outcome, the environmental risk factors (i.e smoking behaviour) that may influence the randomization, the heterogeneous placebo rate of remission and the different statistical methods used to analyze the results. It is important that trials are designed efficiently, done well and complement clinical practice with a careful subject…

Pharmacologymedicine.medical_specialtySettore MED/09 - Medicina InternaRandomizationbusiness.industryGold standardAlternative medicineGeneral Medicinecontrolled clinical trials.inflammatory bowel disease.methodologyInflammatory Bowel Diseasesmedicine.diseasePlaceboInflammatory bowel diseasedigestive system diseaseslaw.inventionTreatment OutcomeRandomized controlled trialEnvironmental risklawmedicineHumansPopulation studyIntensive care medicinebusinessRandomized Controlled Trials as TopicReviews on Recent Clinical Trials
researchProduct

Incidence of Crohn's disease and CARD15 mutation in a small township in Sicily.

2006

Background: The incidence of Crohn's disease (CD) has been shown to be lower in Southern than in Northern Europe. Data on the frequency of the NOD2/CARD15 mutations for Mediterranean area are very scant. Aim: To determine the incidence of CD from 1979 to 2002 in a township in Sicily together with the allele frequency of NOD2/CARD15 mutations in patients, family members and controls, and to determine the allele frequency of these mutations in sporadic CD from other areas of Sicily in comparison with a control population. Methods: Casteltermini is a small town close to Agrigento (Sicily) with a population of 9,130 inhabitants. All the diagnoses of inflammatory bowel disease (IBD) made from 19…

AdultMalemedicine.medical_specialtyPathologyAdolescentEpidemiologyPopulationNod2 Signaling Adaptor ProteinInflammatory bowel diseaseGastroenterologyCrohn DiseaseGene FrequencyInternal medicineEpidemiologyPrevalencemedicineHumansGenetic Predisposition to DiseaseRisk factoreducationAllele frequencySicilyNOD2/CARD15Crohn's diseaseeducation.field_of_studybusiness.industryIncidence (epidemiology)IncidenceMiddle Agedmedicine.diseaseUlcerative colitisdigestive system diseasesCrohn's diseaseMutationColitis UlcerativeFemalebusinessEuropean journal of epidemiology
researchProduct

Mesalazine for the treatment of inflammatory bowel disease

2013

Ulcerative colitis (UC) and Crohn's disease (CD) represent a chronic inflammatory condition of the bowel that often require lifelong medical therapy for the induction and maintenance of the remission. Mesalazine therapies are available both as oral delayed-release and sustained-release formulation, topical formulations and as prodrug.Available literature regarding mesalazine is extensively reviewed in this article, covering its mechanism of action, pharmaceutics and pharmacokinetics, clinical efficacy, safety and tolerability in different settings.Mesalazine has a well-established role in the management of UC. It is the treatment of choice in active and inactive mild-to-moderate UC combinin…

medicine.medical_specialtyColorectal cancerDiseaseGastroenterologyInflammatory bowel diseasechemistry.chemical_compoundCrohn DiseaseMesalazineInternal medicineSecondary PreventionmedicineHumansPharmacology (medical)Intestinal MucosaColitisMesalaminePharmacologyCrohn's diseasebusiness.industryAnti-Inflammatory Agents Non-SteroidalGeneral Medicinemedicine.diseaseUlcerative colitischemistryTolerabilityColitis UlcerativeColorectal NeoplasmsbusinessExpert Opinion on Pharmacotherapy
researchProduct

Methodology for high-quality studies on course and prognosis of inflammatory bowel disease.

2012

Inflammatory bowel diseases (IBDs) are characterized by a chronic course with an alternation of relapses and remissions. Questions about prognosis are important for the patient who wants to know how the disease will affect his/her life and also for clinicians to make management decisions. Correct selection of the patients is the basis for good methodological studies on the course of IBD. A great proportion of data on the course of IBD is derived from a limited number of cohort studies. Studies help to define the endpoints for clinical trials and to identify subsets of patients in whom the prognosis of the disease can be stratified according to clinical features. Specific scientific requirem…

medicine.medical_specialtySettore MED/09 - Medicina InternaReferralmedia_common.quotation_subjectPopulationDiseaseInflammatory bowel diseaseCohort StudiesRisk FactorsNeoplasmsOutcome Assessment Health CareMedicineHumansProspective StudiesTopic HighlighteducationProspective cohort studyIntensive care medicineReferral and ConsultationMETHODOLOGY.COURSE OF DISEASE.INFLAMMATORY BOWEL DISEASEmedia_commonSelection biaseducation.field_of_studybusiness.industryGastroenterologyGeneral Medicinemedicine.diseaseInflammatory Bowel DiseasesPrognosisClinical trialResearch DesignPhysical therapybusinessCohort studyWorld journal of gastroenterology
researchProduct

Infliximab and ulcerative colitis

2006

Expert Opin Biol Ther. 2006 Apr;6(4):401-8. Infliximab and ulcerative colitis. Cottone M, Mocciaro F, Modesto I. Università di Palermo, Istituto di Medicina Generale e Pneumologia, Via Trabucco 180, Palermo, Italy. dickens@tin.it Tumour necrosis factor (TNF)-alpha is an inflammatory cytokine that plays a main role in the inflammatory process underlying inflammatory bowel disease (IBD). Despite the fact that the cytokine profiles associated with ulcerative colitis (UC) and Crohn's disease (CD) are classically considered different (a Th2 pattern in UC and a Th1 pattern in CD), there are several evidences in vitro and in vivo that TNF-alpha has an important role in UC. For this reason, inflixi…

medicine.medical_specialtymedicine.medical_treatmentClinical BiochemistryInflammatory bowel diseaseGastroenterologyGastrointestinal AgentsInternal medicineDrug Discoverymedicineinfliximab. ulcerative colitisHumansColitisPharmacologyGastrointestinal agentbusiness.industryAntibodies MonoclonalPouchitismedicine.diseaseUlcerative colitisInfliximabInfliximabCytokineImmunologyColitis UlcerativeTumor necrosis factor alphabusinessmedicine.drugExpert Opinion on Biological Therapy
researchProduct

The role of portal vein thrombosis in the clinical course of inflammatory bowel diseases: report on three cases and review of the literature.

2012

Inflammatory bowel diseases are associated with an increased risk of vascular complications. The most important are arterial and venous thromboembolisms, which are considered as specific extraintestinal manifestations of inflammatory bowel diseases. Among venous thromboembolism events, portal vein thrombosis has been described in inflammatory bowel diseases. We report three cases of portal vein thrombosis occurring in patients with active inflammatory bowel disease. In two of them, hepatic abscess was present. Furthermore, we performed a systematic review based on the clinical literature published on this topic.

medicine.medical_specialtySettore MED/09 - Medicina InternaHepatologybusiness.industryGastroenterologyClinical courseInflammatory Bowel DiseasesReview ArticleClinical literaturemedicine.diseaseGastroenterologyInflammatory bowel diseasePortal vein thrombosisIncreased riskInternal medicineportal thrombosis.inflammatory bowel diseaseMedicineIn patientlcsh:Diseases of the digestive system. Gastroenterologylcsh:RC799-869businessVenous thromboembolism
researchProduct

Prevalence of Hepatitis B Virus Markers in Patients with Autoimmune Inflammatory Rheumatic Diseases in Italy

2020

Chronic hepatitis B virus (HBV) infection may be reactivated by immunosuppressive drugs in patients with autoimmune inflammatory rheumatic diseases. This study evaluates HBV serum markers&rsquo

0301 basic medicineMicrobiology (medical)HBsAgmedicine.medical_specialtyimmunosuppressive therapyHbv markersmedicine.disease_causeMicrobiologyGastroenterologyArticleVirus03 medical and health sciences0302 clinical medicineVirologyInternal medicinemedicineIn patientlcsh:QH301-705.5Hepatitis B virusbusiness.industryrheumatic patientsvirus diseasesHBV vaccineHBV markersmedicine.diseaseConnective tissue diseasedigestive system diseasesVaccinationTiter030104 developmental biologylcsh:Biology (General)030211 gastroenterology & hepatologybusinessHBV markers; HBV vaccine; immunosuppressive therapy; rheumatic patientsMicroorganisms
researchProduct

Postoperative maintenance therapy for inflammatory bowel disease.

2006

. Curr Opin Gastroenterol. 2006 Jul;22(4):377-81. Postoperative maintenance therapy for inflammatory bowel disease. Cottone M, Orlando A, Modesto I. Department of General Medicine, Pneumology and Nutrition Clinic, Palermo University, Palermo, Italy. PURPOSE OF REVIEW: This review will highlight the knowledge gained from studies published in the year 2005 on maintenance treatment after surgery for inflammatory bowel diseases. RECENT FINDINGS: In Crohn's disease the role of smoking in increasing the risk of relapse and recurrence after surgery is confirmed. Ornidazole seems effective in reducing endoscopic recurrence and clinical relapse after surgery. Probiotics do not appear to be effective…

medicine.medical_specialtyAzathioprineInflammatory bowel diseaseEnteral NutritionMaintenance therapymedicineHumansIntensive care medicineDigestive System Surgical Procedurescrohn.post-operative.Postoperative CareCrohn's diseasebusiness.industryProbioticsGastroenterologyRetrospective cohort studyPouchitismedicine.diseaseInflammatory Bowel DiseasesUlcerative colitisSurgeryAnti-Bacterial AgentsParenteral nutritionTreatment OutcomebusinessImmunosuppressive Agentsmedicine.drugCurrent opinion in gastroenterology
researchProduct

efficacy and safety of endoscopic ballon dilatation of symptomatic gastrointestinal Crohn's disease strictures

2007

researchProduct

Ultrasound in Crohn's disease

2005

researchProduct

a meta-analysis of the placebo rate of clinical relapse and severe endoscopic recurrence in post-operative maintenance therapy in Crohn's disease

2007

researchProduct

Infliximab in moderate to severe sateroid dipendent or refractory severe ulcerative colitis:short term results of 21 case treated

2007

researchProduct

Calprotectin in the prediction of endoscopic post-surgical recurrence in CD

2005

researchProduct

Le malattie infiammatorie dell'intestino

2008

researchProduct

Salycilate in the prevention of post-surgical recurrence in Crohn's disease

2005

researchProduct

THE ROLE OF CARD15 MUTATIONS AND SMOKING IN THE COURSE OF DISEASE IN A MEDITERRANEAN AREA

2008

. Am J Gastroenterol. 2008 Mar;103(3):649-55. The role of CARD15 mutations and smoking in the course of Crohn's disease in a Mediterranean area. Renda MC, Orlando A, Civitavecchia G, Criscuoli V, Maggio A, Mocciaro F, Rossi F, Scimeca D, Modesto I, Oliva L, Cottone M. Ematologia II Ospedale V. Cervello, Palermo, Italy. AIM: To evaluate the role of CARD15 mutations and smoking in the main events of Crohn's disease (CD). PATIENTS AND METHODS: A total of 182 patients with CD were included in a prospective study in order to evaluate the role of CARD15 mutations and smoking in the main outcomes of disease course: first operation and surgical recurrence. The following variables were evaluated in …

researchProduct

Long term follow-up in an incident cohort of 583 pts with CD

2005

researchProduct

NOD2/CARD15 FREQUENCY IN CROHN'DISEASE IN SICILY:AN EPIDEMIOLOGICAL STUDY

2005

researchProduct

EFFICACY AND SAFETY OF ENDOSCOPIC BALLOON DILATION OF SYMPTOMATIC INTESTINAL CROHN'S DISEASE STRICTURES

2008

researchProduct